Mebeverine Hcl Retard (Mebeverine Hydrochloride)

Mebeverine Hydrochloride is used to manage functional gastrointestinal disorders by reducing smooth‑muscle spasms.

• Irritable bowel syndrome (IBS): alleviates abdominal pain, cramping and irregular bowel movements.
• Functional bowel disorder: improves discomfort associated with abnormal gut motility.
• Spastic colon: reduces episodes of colonic spasm and related pain.

• Mebeverine Hydrochloride acts as a direct smooth‑muscle relaxant in the gastrointestinal tract. It inhibits calcium influx into smooth‑muscle cells, which decreases muscle contractility without affecting normal peristalsis. By targeting the enteric smooth muscle, the drug lessens spasmodic activity that contributes to pain and altered bowel habits in functional bowel conditions. The effect is localized to the gut, minimizing systemic anticholinergic activity.

Mebeverine Hydrochloride may cause adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea: mild stomach upset.
• Headache: transient mild headache.
• Dizziness: occasional light‑headedness.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, swelling, or difficulty breathing.
• Severe hypotension: marked drop in blood pressure.
• Cardiac arrhythmia: irregular heartbeat.
• Hepatic dysfunction: elevated liver enzymes.

When prescribing Mebeverine Hydrochloride, clinicians should consider several precautionary measures to ensure safe use.

• Assess medical history: verify absence of known hypersensitivity to mebeverine or related compounds.
• Monitor gastrointestinal conditions: use cautiously in patients with severe obstructive bowel disease.
• Pregnancy and lactation: avoid unless benefit outweighs potential risk, as safety data are limited.
• Drug interactions: review concomitant medications that may affect gut motility.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mebeverine Hydrochloride can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Anticholinergic agents: combined use may increase risk of severe constipation.
• CYP450 inhibitors (e.g., erythromycin): may raise mebeverine plasma levels, enhancing adverse effects.

Moderate Interactions (Monitor Closely)

• Other antispasmodics: additive smooth‑muscle relaxation may lead to excessive GI hypomotility.
• Diuretics: potential for additive hypotensive effect.
• Herbal preparations containing belladonna: may potentiate anticholinergic burden.